Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanc...
Saved in:
| Published in | Journal of gynecologic oncology Vol. 36; no. 1; pp. e72 - 15 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
01.01.2025
대한부인종양학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2005-0380 2005-0399 2005-0399 |
| DOI | 10.3802/jgo.2025.36.e72 |
Cover
| Abstract | This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed. |
|---|---|
| AbstractList | This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed. This review summarized the results of clinical trials in 2024 that were believed to have asignificant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial,INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were includedin early-stage, locally advanced, and recurrent/metastatic cer vical cancer, respectively. Foruterine corpus cancer, updated sur vival data of the four trials (NRG-GY018, RUBY, AtTEnd,DUO-E) for endometrial cancer and the first sur vival data of LMS-04 trial for leiomyosarcomawere described. For ovarian cancer, the final overall sur vival results of PRIMA study werefollowed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different diseaseconditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumabderuxtecan, were briefly addressed. KCI Citation Count: 0 This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed. |
| Author | Yoo, Ji Geun Suh, Dong Hoon Lee, Jung-Yun Lee, Yoo-Young Park, Jeong-Yeol Kim, Jin Hwi Lee, Sung Jong |
| AuthorAffiliation | 4 Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 7 Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea 5 Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea 3 Department of Obstetrics and Gynecology, Uijeongbu St Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea 2 Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea 6 Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 1 Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea |
| AuthorAffiliation_xml | – name: 5 Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea – name: 3 Department of Obstetrics and Gynecology, Uijeongbu St Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea – name: 7 Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea – name: 4 Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – name: 6 Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea – name: 2 Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea – name: 1 Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Sung Jong orcidid: 0000-0002-6077-2649 surname: Lee fullname: Lee, Sung Jong organization: Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea – sequence: 2 givenname: Ji Geun orcidid: 0000-0001-5359-8729 surname: Yoo fullname: Yoo, Ji Geun organization: Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea – sequence: 3 givenname: Jin Hwi orcidid: 0000-0002-1591-1611 surname: Kim fullname: Kim, Jin Hwi organization: Department of Obstetrics and Gynecology, Uijeongbu St Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea – sequence: 4 givenname: Jeong-Yeol orcidid: 0000-0003-2475-7123 surname: Park fullname: Park, Jeong-Yeol organization: Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 5 givenname: Jung-Yun orcidid: 0000-0001-7948-1350 surname: Lee fullname: Lee, Jung-Yun organization: Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea – sequence: 6 givenname: Yoo-Young orcidid: 0000-0001-5902-9877 surname: Lee fullname: Lee, Yoo-Young organization: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea – sequence: 7 givenname: Dong Hoon orcidid: 0000-0002-4312-966X surname: Suh fullname: Suh, Dong Hoon organization: Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39900347$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003169679$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNpVkk1vEzEQhi1URD_gzA35iFCT-mu9ay5VVdEPqRIS9G453vHGzcYO9u5K-QH8b5ykRHCakeeZd8b2e45OQgyA0EdK5rwh7Oqli3NGWDXncg41e4POGCHVjHClTo55Q07Rec4vhMiaNOwdOi1lQrioz9Dv-20AG_vYeYtj2Gdb7AMuquIrXiQwq2GZ4tgt8ZC86TM2ocUwxX7yoStnYIY1hAHnIZkBOg8Zu5iwhTR5a_pLPA6QfABsY9qM-XLfHydTxAK2JhQwv0dvXZGGD6_xAv28-_Z8-zB7-n7_eHvzNLO84cOMEicsiAqcbKu6YZQsWickaxVnYFUrrDKVa2hjnamVBBBAW0laKnnjGn6BvhxUQ3J6Zb2Oxu9jF_Uq6Zsfz4-aljeqmRIFvj7Am3GxhtaWKybT603ya5O2-9b_K8Evi9CkKa0VUWo37vOrQoq_RsiDXvtsoe9NgDhmzctajHEmZEE__TvsOOXvPxXg6gDYFHNO4I4IJXrnBF2coHdO0Fzq4gT-B3qKqXU |
| Cites_doi | 10.1016/j.ygyno.2010.12.352 10.1016/j.ijgc.2024.100001 10.1016/j.annonc.2024.08.2269 10.1038/s41591-024-02981-0 10.1038/s41467-024-52098-8 10.1016/S0140-6736(24)02196-2 10.1016/S1470-2045(24)00486-8 10.3802/jgo.2024.35.e48 10.1016/S0140-6736(24)01808-7 10.1016/j.annonc.2024.08.2242 10.1016/S0140-6736(23)02690-9 10.1056/NEJMoa2302312 10.1016/S1470-2045(23)00648-4 10.1016/S1470-2045(24)00579-5 10.1200/JCO.24.00668 10.1200/JCO.23.02005 10.1056/NEJMoa2308900 10.1136/ijgc-2024-005572 10.1016/S1470-2045(24)00334-6 10.1016/S0140-6736(24)01918-4 10.1056/NEJMoa2403394 10.3802/jgo.2024.35.e66 10.3802/jgo.2024.35.e30 10.1016/S0140-6736(24)00317-9 10.1056/NEJMoa2108330 10.1016/S0959-8049(03)00425-8 10.1016/S0140-6736(23)02405-4 10.1200/JCO.23.02132 10.1016/S1470-2045(21)00006-1 10.1007/s40265-022-01736-w 10.3802/jgo.2024.35.e59 10.1056/NEJMoa2201445 10.1038/s41467-024-46999-x 10.1016/S1470-2045(24)00501-1 10.1016/j.ijgc.2024.101619 10.1002/cncr.35417 10.1056/NEJMoa1910962 10.1016/S1470-2045(24)00006-8 |
| ContentType | Journal Article |
| Copyright | 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2025 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology |
| Copyright_xml | – notice: 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. – notice: 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2025 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| DOI | 10.3802/jgo.2025.36.e72 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-0399 |
| EndPage | 15 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10677294 PMC11790998 39900347 10_3802_jgo_2025_36_e72 |
| Genre | Journal Article Review |
| GroupedDBID | 29K 2WC 5-W 53G 5GY 8JR 8XY 9ZL AAKDD AAYXX ABDBF ACUHS ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION D-I DIK DU5 E3Z EBD EF. F5P GROUPED_DOAJ HYE HZB OK1 RPM CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR M~E |
| ID | FETCH-LOGICAL-c383t-10f4ce45ef6d578210bdf462d932ec9d4c9a5f818cfa796ee4e1d60d1638f83 |
| ISSN | 2005-0380 2005-0399 |
| IngestDate | Wed Jan 29 10:22:22 EST 2025 Thu Aug 21 18:38:34 EDT 2025 Fri Jul 11 00:21:54 EDT 2025 Wed May 21 12:14:39 EDT 2025 Tue Jul 01 02:37:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Immunoconjugates Molecular Targeted Therapy Gynecologic Neoplasms Immunotherapy Poly(ADP-Ribose) Polymerase Inhibitor |
| Language | English |
| License | 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c383t-10f4ce45ef6d578210bdf462d932ec9d4c9a5f818cfa796ee4e1d60d1638f83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Sung Jong Lee and Ji Geun Yoo equally contributed to this report. https://doi.org/10.3802/jgo.2025.36.e72 |
| ORCID | 0000-0002-1591-1611 0000-0001-7948-1350 0000-0002-4312-966X 0000-0003-2475-7123 0000-0002-6077-2649 0000-0001-5902-9877 0000-0001-5359-8729 |
| OpenAccessLink | http://dx.doi.org/10.3802/jgo.2025.36.e72 |
| PMID | 39900347 |
| PQID | 3163223246 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10677294 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11790998 proquest_miscellaneous_3163223246 pubmed_primary_39900347 crossref_primary_10_3802_jgo_2025_36_e72 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-01 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of gynecologic oncology |
| PublicationTitleAlternate | J Gynecol Oncol |
| PublicationYear | 2025 |
| Publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 대한부인종양학회 |
| Publisher_xml | – name: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology – name: 대한부인종양학회 |
| References | Van Gorp (10.3802/jgo.2025.36.e72_ref27) 2024; 35 Jiang (10.3802/jgo.2025.36.e72_ref40) 2024; 30 Oaknin (10.3802/jgo.2025.36.e72_ref14) 2024; 403 Plante (10.3802/jgo.2025.36.e72_ref4) 2025; 35 Banerjee (10.3802/jgo.2025.36.e72_ref20) 2024; 130 González-Martín (10.3802/jgo.2025.36.e72_ref38) 2024; 42 Marth (10.3802/jgo.2025.36.e72_ref29) 2024 Monk (10.3802/jgo.2025.36.e72_ref36) 2024; 35 Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration (10.3802/jgo.2025.36.e72_ref6) 2003; 39 Biagioli (10.3802/jgo.2025.36.e72_ref25) 2024; 25 Makker (10.3802/jgo.2025.36.e72_ref28) 2022; 386 Eskander (10.3802/jgo.2025.36.e72_ref19) 2024; 22 Shi (10.3802/jgo.2025.36.e72_ref39) 2021; 22 Eerkens (10.3802/jgo.2025.36.e72_ref30) 2024; 15 Kouhen (10.3802/jgo.2025.36.e72_ref12) 2024; 25 Abuhelwa (10.3802/jgo.2025.36.e72_ref43) 2022; 82 Lindegaard (10.3802/jgo.2025.36.e72_ref7) 2024; 34 Takekuma (10.3802/jgo.2025.36.e72_ref3) 2024; 35 Shim (10.3802/jgo.2025.36.e72_ref21) 2024; 35 González-Martín (10.3802/jgo.2025.36.e72_ref33) 2019; 381 Meric-Bernstam (10.3802/jgo.2025.36.e72_ref42) 2024; 42 Plante (10.3802/jgo.2025.36.e72_ref2) 2024; 390 Colombo (10.3802/jgo.2025.36.e72_ref23) 2024; 25 Lorusso (10.3802/jgo.2025.36.e72_ref9) 2024; 404 Han (10.3802/jgo.2025.36.e72_ref18) 2024; 35 Gouveia (10.3802/jgo.2025.36.e72_ref34) 2025 Sun (10.3802/jgo.2025.36.e72_ref17) 2024; 404 Eskander (10.3802/jgo.2025.36.e72_ref22) 2023; 388 Xiang (10.3802/jgo.2025.36.e72_ref16) 2024; 25 Ray-Coquard (10.3802/jgo.2025.36.e72_ref41) 2024; 15 Gennigens (10.3802/jgo.2025.36.e72_ref11) 2024; 404 Pautier (10.3802/jgo.2025.36.e72_ref32) 2024; 391 10.3802/jgo.2025.36.e72_ref37 Schmeler (10.3802/jgo.2025.36.e72_ref1) 2011; 120 Yang (10.3802/jgo.2025.36.e72_ref10) 2024; 25 Lin (10.3802/jgo.2025.36.e72_ref24) 2024; 25 Cercek (10.3802/jgo.2025.36.e72_ref31) 2022; 386 Lorusso (10.3802/jgo.2025.36.e72_ref8) 2024; 403 Westin (10.3802/jgo.2025.36.e72_ref26) 2024; 42 García (10.3802/jgo.2025.36.e72_ref13) 2024; 35 Wu (10.3802/jgo.2025.36.e72_ref35) 2024 Ramirez (10.3802/jgo.2025.36.e72_ref5) 2025; 35 Mileshkin (10.3802/jgo.2025.36.e72_ref15) 2024; 403 |
| References_xml | – volume: 120 start-page: 321 year: 2011 ident: 10.3802/jgo.2025.36.e72_ref1 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2010.12.352 – volume: 35 start-page: 100001 year: 2025 ident: 10.3802/jgo.2025.36.e72_ref4 publication-title: Int J Gynecol Cancer doi: 10.1016/j.ijgc.2024.100001 – volume: 35 start-page: S1223 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref36 publication-title: Ann Oncol doi: 10.1016/j.annonc.2024.08.2269 – volume: 30 start-page: 2181 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref40 publication-title: Nat Med doi: 10.1038/s41591-024-02981-0 – volume: 15 start-page: 7695 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref30 publication-title: Nat Commun doi: 10.1038/s41467-024-52098-8 – volume: 404 start-page: 1618 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref17 publication-title: Lancet doi: 10.1016/S0140-6736(24)02196-2 – ident: 10.3802/jgo.2025.36.e72_ref37 – volume: 25 start-page: e534 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref24 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00486-8 – volume: 35 start-page: e48 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref3 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2024.35.e48 – volume: 404 start-page: 1321 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref9 publication-title: Lancet doi: 10.1016/S0140-6736(24)01808-7 – year: 2024 ident: 10.3802/jgo.2025.36.e72_ref29 publication-title: J Clin Oncol – volume: 35 start-page: 968 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref27 publication-title: Ann Oncol doi: 10.1016/j.annonc.2024.08.2242 – volume: 403 start-page: 2 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref15 publication-title: Lancet doi: 10.1016/S0140-6736(23)02690-9 – volume: 388 start-page: 2159 year: 2023 ident: 10.3802/jgo.2025.36.e72_ref22 publication-title: N Engl J Med doi: 10.1056/NEJMoa2302312 – volume: 25 start-page: e94 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref12 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(23)00648-4 – volume: 25 start-page: e536 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref25 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00579-5 – volume: 42 start-page: 4294 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref38 publication-title: J Clin Oncol doi: 10.1200/JCO.24.00668 – volume: 42 start-page: 47 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref42 publication-title: J Clin Oncol doi: 10.1200/JCO.23.02005 – volume: 390 start-page: 819 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref2 publication-title: N Engl J Med doi: 10.1056/NEJMoa2308900 – volume: 34 start-page: 1940 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref7 publication-title: Int J Gynecol Cancer doi: 10.1136/ijgc-2024-005572 – volume: 22 start-page: 28 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref19 publication-title: Clin Adv Hematol Oncol – volume: 25 start-page: 1135 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref23 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00334-6 – volume: 404 start-page: 1282 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref11 publication-title: Lancet doi: 10.1016/S0140-6736(24)01918-4 – volume: 391 start-page: 789 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref32 publication-title: N Engl J Med doi: 10.1056/NEJMoa2403394 – year: 2024 ident: 10.3802/jgo.2025.36.e72_ref35 publication-title: Ann Oncol – volume: 35 start-page: e66 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref21 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2024.35.e66 – volume: 35 start-page: e30 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref13 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2024.35.e30 – volume: 403 start-page: 1341 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref8 publication-title: Lancet doi: 10.1016/S0140-6736(24)00317-9 – year: 2025 ident: 10.3802/jgo.2025.36.e72_ref34 publication-title: Int J Gynecol Cancer – volume: 386 start-page: 437 year: 2022 ident: 10.3802/jgo.2025.36.e72_ref28 publication-title: N Engl J Med doi: 10.1056/NEJMoa2108330 – volume: 39 start-page: 2470 year: 2003 ident: 10.3802/jgo.2025.36.e72_ref6 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(03)00425-8 – volume: 403 start-page: 31 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref14 publication-title: Lancet doi: 10.1016/S0140-6736(23)02405-4 – volume: 42 start-page: 283 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref26 publication-title: J Clin Oncol doi: 10.1200/JCO.23.02132 – volume: 22 start-page: 439 year: 2021 ident: 10.3802/jgo.2025.36.e72_ref39 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00006-1 – volume: 82 start-page: 979 year: 2022 ident: 10.3802/jgo.2025.36.e72_ref43 publication-title: Drugs doi: 10.1007/s40265-022-01736-w – volume: 35 start-page: e59 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref18 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2024.35.e59 – volume: 386 start-page: 2363 year: 2022 ident: 10.3802/jgo.2025.36.e72_ref31 publication-title: N Engl J Med doi: 10.1056/NEJMoa2201445 – volume: 15 start-page: 5931 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref41 publication-title: Nat Commun doi: 10.1038/s41467-024-46999-x – volume: 25 start-page: e535 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref16 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00501-1 – volume: 35 start-page: 101619 year: 2025 ident: 10.3802/jgo.2025.36.e72_ref5 publication-title: Int J Gynecol Cancer doi: 10.1016/j.ijgc.2024.101619 – volume: 130 start-page: 3082 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref20 publication-title: Cancer doi: 10.1002/cncr.35417 – volume: 381 start-page: 2391 year: 2019 ident: 10.3802/jgo.2025.36.e72_ref33 publication-title: N Engl J Med doi: 10.1056/NEJMoa1910962 – volume: 25 start-page: e95 year: 2024 ident: 10.3802/jgo.2025.36.e72_ref10 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00006-8 |
| SSID | ssj0067082 |
| Score | 2.347109 |
| SecondaryResourceType | review_article |
| Snippet | This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic... This review summarized the results of clinical trials in 2024 that were believed to have asignificant impact on clinical practice in the field of gynecologic... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e72 |
| SubjectTerms | Clinical Trials as Topic Female Humans Ovarian Neoplasms - therapy Review Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - therapy Uterine Neoplasms - therapy 산부인과학 |
| Title | Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39900347 https://www.proquest.com/docview/3163223246 https://pubmed.ncbi.nlm.nih.gov/PMC11790998 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003169679 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Gynecologic Oncology, 2025, 36(1), , pp.1-15 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF2lRUJcEN-ELy2CA1Lq4Nrrtc0NIWipVC4tUjmtnPU4mCCnSuIiuPNL-KPM7HodxwSpcEkixxlv8l5mZ7yzbxh7nmoZgcxSz9c69kSYF14mQHsgI4Q7xDnJiOkcf5CHH8XRWXQ2GPzqVC3Vq8lY_9i6r-R_UMVjiCvtkv0HZFujeABfI774iAjj46UwPvhegbbeazSvtJVTKqtRgFMipfqY7mYz14nH9OewisyAPunCNohwZebLldOMMIWH2rgQ0wxgRE0fKBbFPPW8Xrpyz_kFZtnoHDTRplkS-jPInW4ZYa8G6ATdDd3En64dkF0NKkcHUHeKBOx-btLm-lauV75sqfcRoAHvE8y_dm9jBFHnNobxdkYS1Q9tW6cxdI_ZDkrOXVu9lC4t-7MAGiFV2S9T2twZRONQjsH2B9rU2-7Ng211IuZFZEKhAUUGVCgVGthhV4IYAzSXt9vpXsa-6UjWjt_qR5GBl70RbIQ-O9Wi2JbV9ItzO9HO6Q12vUGQv7acu8kGUN1iV4-bQozb7GeHetwBy8uKE_Ve8S7xuCUeR9JwRzzeEo-viceReNwRb483tOOWdnvm8w3peEO6O-zk3dvTN4de09HD02ESrnDOL4QGEUEhc-qjsO9P8kLIIMcsAnSaC51mUYExpC6yOJUAAvZz6eeUNBRJeJftVvMK7jMepKCTPEM7Ey20TlI_z9DtiIJWsdM4GrIX7qdW51a2Rf0F1iF7hlComS4VSa3TM54wWyhMKN8ro7AYpGLInjqoFDpgWlXLKpjXSxXi4ALKS-SQ3bPQtZdE6pIAVDxkyQao7Ql0xc13qvKzEXknqUbM3pIHl_8mD9m19T_rEdtdLWp4jCHzavLEUPY308nGig |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gynecologic+oncology+in+2024%3A+breakthrough+trials+and+evolving+treatment+strategies+for+cervical%2C+uterine+corpus%2C+and+ovarian+cancers&rft.jtitle=Journal+of+gynecologic+oncology&rft.au=Lee%2C+Sung+Jong&rft.au=Yoo%2C+Ji+Geun&rft.au=Kim%2C+Jin+Hwi&rft.au=Park%2C+Jeong-Yeol&rft.date=2025-01-01&rft.issn=2005-0380&rft.eissn=2005-0399&rft.volume=36&rft.issue=1&rft_id=info:doi/10.3802%2Fjgo.2025.36.e72&rft.externalDBID=n%2Fa&rft.externalDocID=10_3802_jgo_2025_36_e72 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-0380&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-0380&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-0380&client=summon |